Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.

联合配制的 Bictegravir / 恩曲他滨 / 替诺福韦 Alafenamide 用于性侵犯后暴露后预防 ： 一项回顾性现实世界研究。

• 影响指数: 4.423
• 发表时间: 2024 Aug
• 来源期刊: Open Forum Infect Dis
• DOI: 10.1093/ofid/ofae436
• PMID: 39139581
• 文章类型: Journal Article
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Teresita de Jesús CL,Edgar PB,Carlos Ruben NC,Marla TR,Juan Carlos RA,Raúl Adrián CF,Andrea GR

关键词: HIV; INSTI; bictegravir/emtricitabine/tenofovir alafenamide; post-exposure prophylaxis; sexual assault

Abstract

We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.

摘要

我们报告了比替拉韦/恩曲他滨/替诺福韦艾拉酚胺在性侵犯病例中用于非职业暴露后预防的经验。2021年6月至2023年10月，39人完成了为期28天的随访；41%的人出现了一些副作用。1人因皮疹停药。在随访期间，没有人血清转化为HIV。